ECSP055708A - Sales bencenosulfonato de derivadosde 4-fluoro-2-cianopirrolidina - Google Patents

Sales bencenosulfonato de derivadosde 4-fluoro-2-cianopirrolidina

Info

Publication number
ECSP055708A
ECSP055708A EC2005005708A ECSP055708A ECSP055708A EC SP055708 A ECSP055708 A EC SP055708A EC 2005005708 A EC2005005708 A EC 2005005708A EC SP055708 A ECSP055708 A EC SP055708A EC SP055708 A ECSP055708 A EC SP055708A
Authority
EC
Ecuador
Prior art keywords
fluoro
cyanopirrolidine
bencenosulfonate
derivatives
stability
Prior art date
Application number
EC2005005708A
Other languages
English (en)
Inventor
Hiroshi Fukushima
Akira Hiratate
Masato Takahashi
Kazuya Kameo
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of ECSP055708A publication Critical patent/ECSP055708A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una sal bencenosulfonato de (2S, 4S)-2-ciano-4-fluoro-1-[(2-hidroxi-1,1-dimetil)etilamino]acetilpirrolidina muestra una excelente actividad inhibidora de DPPIV y tiene propiedades requeridas como un medicamento, por ejemplo, una estabilidad alta; este compuesto se puede obtener fácilmente en la forma de cristales altamente estables que tienen una forma uniforme y tienen una alta estabilidad en estado sólido.
EC2005005708A 2002-08-29 2005-03-28 Sales bencenosulfonato de derivadosde 4-fluoro-2-cianopirrolidina ECSP055708A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002249821 2002-08-29

Publications (1)

Publication Number Publication Date
ECSP055708A true ECSP055708A (es) 2005-08-11

Family

ID=31972599

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005708A ECSP055708A (es) 2002-08-29 2005-03-28 Sales bencenosulfonato de derivadosde 4-fluoro-2-cianopirrolidina

Country Status (19)

Country Link
US (1) US7304166B2 (es)
EP (1) EP1535907A4 (es)
JP (1) JP3746063B2 (es)
KR (1) KR100582141B1 (es)
CN (1) CN1310885C (es)
AU (1) AU2003261748B2 (es)
BR (1) BR0313831A (es)
CA (1) CA2496623C (es)
EA (1) EA007613B1 (es)
EC (1) ECSP055708A (es)
HK (1) HK1082497A1 (es)
HR (1) HRP20050205A2 (es)
MX (1) MXPA05002253A (es)
NO (1) NO20050867L (es)
NZ (1) NZ538956A (es)
PL (1) PL374664A1 (es)
UA (1) UA78104C2 (es)
WO (1) WO2004020407A1 (es)
ZA (1) ZA200501418B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US20080114053A1 (en) 2005-01-27 2008-05-15 Mitsui Chemicals, Inc. Method for Producing Fluorinated Proline Derivative
JP2008024592A (ja) * 2005-01-28 2008-02-07 Taisho Pharmaceut Co Ltd シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
MX2007011546A (es) * 2005-03-22 2007-10-19 Hoffmann La Roche Nueva sal y polimorfos del inhibidor de dipeptidil-peptidasa iv.
DK1942898T4 (da) 2005-09-14 2014-06-02 Takeda Pharmaceutical Dipeptidylpeptidase-inhibitorer til behandling af diabetes
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008120813A1 (ja) 2007-04-03 2008-10-09 Mitsubishi Tanabe Pharma Corporation ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
CL2008003653A1 (es) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CN102918027A (zh) 2010-04-06 2013-02-06 艾尼纳制药公司 Gpr119受体调节剂和对与所述受体有关的障碍的治疗
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432987A (en) 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
JP3107784B2 (ja) 1996-12-26 2000-11-13 宇部興産株式会社 光学活性ピペリジン誘導体の酸付加塩及びその製法
TW486475B (en) 1996-12-26 2002-05-11 Ube Industries Acid addition salt of optically active piperidine compound and process for preparing the same
US6252063B1 (en) 1998-12-01 2001-06-26 Merck & Co., Inc. Crystalline salts of a carbapenem antibiotic
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives

Also Published As

Publication number Publication date
AU2003261748A1 (en) 2004-03-19
CA2496623A1 (en) 2004-03-11
BR0313831A (pt) 2005-07-05
EA200500420A1 (ru) 2005-08-25
EP1535907A1 (en) 2005-06-01
NZ538956A (en) 2006-08-31
JP3746063B2 (ja) 2006-02-15
HRP20050205A2 (en) 2005-10-31
HK1082497A1 (en) 2006-06-09
EP1535907A4 (en) 2006-11-29
ZA200501418B (en) 2006-10-25
US7304166B2 (en) 2007-12-04
UA78104C2 (en) 2007-02-15
CN1678575A (zh) 2005-10-05
KR100582141B1 (ko) 2006-05-22
WO2004020407A1 (ja) 2004-03-11
EA007613B1 (ru) 2006-12-29
KR20050059094A (ko) 2005-06-17
PL374664A1 (en) 2005-10-31
MXPA05002253A (es) 2005-06-08
US20060106087A1 (en) 2006-05-18
NO20050867L (no) 2005-02-18
JPWO2004020407A1 (ja) 2005-12-15
CA2496623C (en) 2008-02-12
AU2003261748B2 (en) 2006-11-23
CN1310885C (zh) 2007-04-18

Similar Documents

Publication Publication Date Title
ECSP055708A (es) Sales bencenosulfonato de derivadosde 4-fluoro-2-cianopirrolidina
CY1122777T1 (el) Στερεη φαρμακευτικη δοσολογικη φαρμακοτεχνικη μορφη που περιεχει λοπιναβιρη
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
AR019507A1 (es) Uso de los inhibidores de cyp2d6 en terapias de combinacion
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
SE0100901D0 (sv) New composition
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
AR063188A1 (es) Compuestos intermediarios para la preparacion de trans -5-cloro-2-netil-2,3,3a,12b- tetrahidro-1h-dibenz (2,3:6,7)- oxepina (4,5c) pirrol
AR052447A1 (es) Etansulfonato de 1-(2-metipropil)-1h-imidazo[4,5-c] [1,5] naftiridin-4- amina y metansulfonato de 1-(2- metipropil)-1h-imidazo[4,5 -c] [1,5] naftiridin-4-amina
ECSP088258A (es) Inhibidores de serina proteasas
CR7995A (es) Nueva difenilazetidinona con caracteristicas fisiologicas mejoradas correspondiente metodo de produccion , medicamentos que lo contienen y uso de los mismos
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
ECSP034444A (es) Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina
ATE464307T1 (de) Mif-hemmer
UY28348A1 (es) Compuestos novedosos
BRPI0620229A8 (pt) formulação
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
AR027016A1 (es) Proceso para la estabilizacion de vino
NO20043114L (no) Bredspektrede heterocyklisk substituerte fenylinneholdende sulfonamid-HIV-proteaseinhibitorer
NO20025738D0 (no) Metode
CO5631429A2 (es) Combinacion farmaceutica
PA8554901A1 (es) Esteres de analogos de 3-desoxi-vitamina d3